Esperion Therapeutics (ESPR) Stock Price Down 0.4%

Esperion Therapeutics Inc (NASDAQ:ESPR) shares traded down 0.4% during mid-day trading on Friday . The stock traded as low as $69.68 and last traded at $70.62. 345,850 shares changed hands during trading, a decline of 46% from the average session volume of 636,858 shares. The stock had previously closed at $70.37.

Several research analysts recently issued reports on the stock. Needham & Company LLC raised shares of Esperion Therapeutics from a “buy” rating to a “strong-buy” rating and raised their target price for the stock from $72.00 to $81.00 in a report on Thursday, December 14th. JPMorgan Chase & Co. reissued a “neutral” rating and set a $65.00 target price (up previously from $55.00) on shares of Esperion Therapeutics in a report on Wednesday, February 21st. ValuEngine raised shares of Esperion Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Deutsche Bank raised their target price on shares of Esperion Therapeutics to $100.00 and gave the stock a “buy” rating in a report on Friday, March 9th. Finally, BidaskClub cut shares of Esperion Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, March 9th. Seven analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $90.62.

How to Become a New Pot Stock Millionaire

The stock has a market cap of $1,995.93, a PE ratio of -10.00 and a beta of 2.45.

Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings results on Tuesday, February 20th. The biopharmaceutical company reported ($1.44) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.80) by $0.36. During the same quarter last year, the business posted ($1.29) EPS. equities research analysts expect that Esperion Therapeutics Inc will post -5.66 earnings per share for the current year.

In related news, Director Nicole Vitullo sold 11,674 shares of the firm’s stock in a transaction on Thursday, January 25th. The shares were sold at an average price of $71.79, for a total transaction of $838,076.46. Following the sale, the director now owns 3,177 shares in the company, valued at $228,076.83. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 32.50% of the stock is currently owned by company insiders.

A number of hedge funds have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp grew its position in Esperion Therapeutics by 0.7% during the fourth quarter. Bank of New York Mellon Corp now owns 116,224 shares of the biopharmaceutical company’s stock valued at $7,652,000 after buying an additional 852 shares during the period. First Mercantile Trust Co. grew its position in Esperion Therapeutics by 56.0% during the fourth quarter. First Mercantile Trust Co. now owns 4,233 shares of the biopharmaceutical company’s stock valued at $279,000 after buying an additional 1,519 shares during the period. Russell Investments Group Ltd. grew its position in Esperion Therapeutics by 8.3% during the third quarter. Russell Investments Group Ltd. now owns 25,072 shares of the biopharmaceutical company’s stock valued at $1,257,000 after buying an additional 1,913 shares during the period. Rhumbline Advisers grew its position in Esperion Therapeutics by 10.6% during the third quarter. Rhumbline Advisers now owns 20,500 shares of the biopharmaceutical company’s stock valued at $1,027,000 after buying an additional 1,960 shares during the period. Finally, American International Group Inc. grew its position in Esperion Therapeutics by 21.6% during the third quarter. American International Group Inc. now owns 11,257 shares of the biopharmaceutical company’s stock valued at $564,000 after buying an additional 2,001 shares during the period. Institutional investors own 91.66% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Esperion Therapeutics (ESPR) Stock Price Down 0.4%” was originally published by Ticker Report and is owned by of Ticker Report. If you are accessing this report on another website, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.tickerreport.com/banking-finance/3293991/esperion-therapeutics-espr-stock-price-down-0-4.html.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

TCF Financial  PT Raised to $28.00
TCF Financial PT Raised to $28.00
Huntsman  Rating Lowered to Hold at Zacks Investment Research
Huntsman Rating Lowered to Hold at Zacks Investment Research
Japan Tobacco  Stock Rating Lowered by Zacks Investment Research
Japan Tobacco Stock Rating Lowered by Zacks Investment Research
Liberum Capital Increases Domino’s Pizza Group  Price Target to GBX 280
Liberum Capital Increases Domino’s Pizza Group Price Target to GBX 280
Pacific Ethanol  Stock Rating Lowered by ValuEngine
Pacific Ethanol Stock Rating Lowered by ValuEngine
Q1 2018 EPS Estimates for Whiting Petroleum Corp Increased by SunTrust Banks
Q1 2018 EPS Estimates for Whiting Petroleum Corp Increased by SunTrust Banks


© 2006-2018 Ticker Report. Google+.